Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Pharmacokinetics of nelfinavir and indinavir in HIV-1-infected pregnant women.

Kosel BW, Beckerman KP, Hayashi S, Homma M, Aweeka FT.

AIDS. 2003 May 23;17(8):1195-9.

PMID:
12819521
2.

High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy.

Goujard C, Legrand M, Panhard X, Diquet B, Duval X, Peytavin G, Vincent I, Katlama C, Leport C, Bonnet B, Salmon-Céron D, Mentré F, Taburet AM; COPHAR1-ANRS 102 Study Group..

Clin Pharmacokinet. 2005;44(12):1267-78.

PMID:
16372824
3.

Determination of indinavir and nelfinavir trough plasma concentration efficacy thresholds according to virological response in HIV-infected patients.

Duval X, Peytavin G, Albert I, Bénoliel S, Ecobichon JL, Brun-Vézinet F, Mentré F, Leport C, Vildé JL.

HIV Med. 2004 Jul;5(4):307-13.

4.

Therapeutic drug monitoring of indinavir and nelfinavir to assess adherence to therapy in human immunodeficiency virus-infected children.

van Rossum AM, Bergshoeff AS, Fraaij PL, Hugen PW, Hartwig NG, Geelen SP, Wolfs TF, Weemaes CM, De Groot R, Burger DM.

Pediatr Infect Dis J. 2002 Aug;21(8):743-7.

PMID:
12192162
5.

Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals.

Burger D, Hugen P, Reiss P, Gyssens I, Schneider M, Kroon F, Schreij G, Brinkman K, Richter C, Prins J, Aarnoutse R, Lange J; ATHENA Cohort Study Group..

AIDS. 2003 May 23;17(8):1157-65.

PMID:
12819517
6.

Alteration in cytochrome P450 3A4 activity as measured by a urine cortisol assay in HIV-1-infected pregnant women and relationship to antiretroviral pharmacokinetics.

Aweeka FT, Hu C, Huang L, Best BM, Stek A, Lizak P, Burchett SK, Read JS, Watts H, Mirochnick M, Capparelli EV; International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT) P1026s Protocol Team..

HIV Med. 2015 Mar;16(3):176-83. doi: 10.1111/hiv.12195.

7.

Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression.

Ford J, Cornforth D, Hoggard PG, Cuthbertson Z, Meaden ER, Williams I, Johnson M, Daniels E, Hsyu P, Back DJ, Khoo SH.

Antivir Ther. 2004 Feb;9(1):77-84.

PMID:
15040539
8.

Reduced lopinavir exposure during pregnancy.

Stek AM, Mirochnick M, Capparelli E, Best BM, Hu C, Burchett SK, Elgie C, Holland DT, Smith E, Tuomala R, Cotter A, Read JS.

AIDS. 2006 Oct 3;20(15):1931-9.

PMID:
16988514
9.

Protease inhibitor drug levels in the management of human immunodeficiency virus-1 antiretroviral therapy.

Urban AW, Bean P, Aziz D, Graziano FM, Neudeck BL.

Int J STD AIDS. 2003 Feb;14(2):103-8.

PMID:
12662388
10.

Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery.

Gingelmaier A, Kurowski M, Kästner R, Eberle J, Mylonas I, Belohradsky BH, Friese K, Grubert TA.

AIDS. 2006 Aug 22;20(13):1737-43.

PMID:
16931938
11.

Nelfinavir plasma concentrations are low during pregnancy.

Nellen JF, Schillevoort I, Wit FW, Bergshoeff AS, Godfried MH, Boer K, Lange JM, Burger DM, Prins JM.

Clin Infect Dis. 2004 Sep 1;39(5):736-40.

PMID:
15356791
12.

In-vitro and in-vivo pharmacokinetic interactions of amprenavir, an HIV protease inhibitor, with other current HIV protease inhibitors in rats.

Shibata N, Gao W, Okamoto H, Kishida T, Yoshikawa Y, Takada K.

J Pharm Pharmacol. 2002 Feb;54(2):221-9.

PMID:
11848286
13.

The long-term pharmacokinetics and safety of adding low-dose ritonavir to a nelfinavir 1,250 mg twice-daily regimen in HIV-infected patients.

Justesen US, Hansen IM, Andersen AB, Klitgaard NA, Black FT, Gerstoft J, Mathiesen LR, Pedersen C.

HIV Med. 2005 Sep;6(5):334-40.

14.

Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.

Rudin C, Burri M, Shen Y, Rode R, Nadal D; Pediatric Infectious Disease Group of Switzerland.; Swiss Mother and Child HIV Cohort Study (MoCHiV)..

Pediatr Infect Dis J. 2008 May;27(5):431-7. doi: 10.1097/INF.0b013e3181646d5a.

PMID:
18382386
15.

Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus.

Chappuy H, Tréluyer JM, Rey E, Dimet J, Fouché M, Firtion G, Pons G, Mandelbrot L.

Am J Obstet Gynecol. 2004 Aug;191(2):558-62.

PMID:
15343237
16.

Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer.

Ripamonti D, Cattaneo D, Maggiolo F, Airoldi M, Frigerio L, Bertuletti P, Ruggeri M, Suter F.

AIDS. 2007 Nov 30;21(18):2409-15.

PMID:
18025877
17.

Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir.

Sulkowski MS, Mehta SH, Chaisson RE, Thomas DL, Moore RD.

AIDS. 2004 Nov 19;18(17):2277-84.

PMID:
15577540
18.

An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children.

Saitoh A, Singh KK, Powell CA, Fenton T, Fletcher CV, Brundage R, Starr S, Spector SA.

AIDS. 2005 Mar 4;19(4):371-80.

PMID:
15750390
19.

Pharmacokinetic interaction between chemotherapy for non-Hodgkin's lymphoma and protease inhibitors in HIV-1-infected patients.

Cruciani M, Gatti G, Vaccher E, Di Gennaro G, Cinelli R, Bassetti M, Tirelli U, Bassetti D.

J Antimicrob Chemother. 2005 Apr;55(4):546-9.

PMID:
15728147
20.

Pharmacokinetics and tolerability of a combination of indinavir, lopinavir and ritonavir in multiply pretreated HIV-1 infected adults.

von Hentig N, Müller A, Rottmann C, Lutz T, Klauke S, Kurowski M, Staszewski S, Harder S.

Eur J Med Res. 2006 Jun 30;11(6):236-44.

PMID:
16820336

Supplemental Content

Support Center